Adjuvant FEC Versus EP in Breast Cancer (MIG5)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,055

Participants

Timeline

Start Date

November 30, 1996

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Breast CancerChemotherapy, Adjuvant
Interventions
DRUG

5-fluorouracil

600 mg/m2 intravenously on day 1, every 21 days for six cycles

DRUG

epirubicin

60 mg/m2 intravenously on day 1, every 21 days for six cyles

DRUG

cyclophosphamide

600 mg/m2, intravenously on day 1, every 21 days for six cycles

DRUG

epirubicin

90 mg/m2 on day 1, every 21 days for four cycles

DRUG

paclitaxel

175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles

Trial Locations (8)

10126

Antonio Durando, Torino

Saverio Danese, Torino

12051

Federico Castiglione, Alba

12100

Ornella Garrone, Cuneo

16132

Lucia Del Mastro, Genoa

46100

Giovanna Cavazzini, Mantova

56100

Andrea Michelotti, Pisa

07100

Tiziana Scotto, Sassari

All Listed Sponsors
lead

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

OTHER

NCT02450058 - Adjuvant FEC Versus EP in Breast Cancer (MIG5) | Biotech Hunter | Biotech Hunter